WallStSmart

AbbVie Inc (ABBV)vsCross Country Healthcare Inc (CCRN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 6326% more annual revenue ($64.39B vs $1.00B). ABBV leads profitability with a 9.8% profit margin vs -9.8%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).

ABBV

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 8.5Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

CCRN

Hold

36

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.7Quality: 9.0
Piotroski: 4/9Altman Z: 4.25
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-73.5%)

Margin of Safety

-73.5%

Fair Value

$152.16

Current Price

$263.96

$111.80 premium

UndervaluedFair: $152.16Overvalued
CCRNUndervalued (+37.2%)

Margin of Safety

+37.2%

Fair Value

$13.16

Current Price

$13.25

$0.09 discount

UndervaluedFair: $13.16Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$454.36B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
40.0%10/10

Strong operational efficiency at 40.0%

EPS GrowthGrowth
290.4%10/10

Earnings expanding 290.4% YoY

Debt/EquityHealth
-11.9310/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.528/10

Growing faster than its price suggests

CCRN3 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.2510/10

Safe zone — low bankruptcy risk

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
72.0x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

CCRN4 concerns · Avg: 2.3/10
Market CapQuality
$428.06M3/10

Smaller company, higher risk/reward

PEG RatioValuation
12.622/10

Expensive relative to growth rate

Return on EquityProfitability
-31.5%2/10

ROE of -31.5% — below average capital efficiency

Revenue GrowthGrowth
-17.8%2/10

Revenue declined 17.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.

Bull Case : CCRN

The strongest argument for CCRN centers on Price/Book, Debt/Equity, Altman Z-Score.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.

Bear Case : CCRN

The primary concerns for CCRN are Market Cap, PEG Ratio, Return on Equity.

Key Dynamics to Monitor

ABBV profiles as a value stock while CCRN is a turnaround play — different risk/reward profiles.

CCRN carries more volatility with a beta of 0.45 — expect wider price swings.

ABBV is growing revenue faster at 10.2% — sustainability is the question.

ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (73/100 vs 36/100) and 10.2% revenue growth. CCRN offers better value entry with a 37.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Cross Country Healthcare Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cross Country Healthcare, Inc. provides talent management and other consulting services for healthcare clients in the United States. The company is headquartered in Boca Raton, Florida.

Visit Website →

Want to dig deeper into these stocks?